Efficacy and Safety of Acupoint Catgut Embedding for Obesity Associated with Polycystic Ovary Syndrome: A Qualitative and Quantitative Analysis
Authors:
- Xing-Xian LiXLXing-Xian Li
- Zhuo-Ya HuZHZhuo-Ya Hu
- Dong-Ni YuanDYDong-Ni Yuan
- Jun-Xin ZhaoJZJun-Xin Zhao
- Wen-Bin MaWMWen-Bin Ma
- Lei LanLLLei Lan
Open Access
- 1 February 2026
- journal article
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-15
Abstract
Obesity is common in women with polycystic ovary syndrome (PCOS) and can exacerbate PCOS symptoms. Although Acupoint catgut embedding (ACE) is frequently used to treat the clinical symptoms of simple obesity, it is unclear how it will affect obesity associated with PCOS. We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) to evaluate the effectiveness of ACE in treating obesity in women with PCOS. We searched databases from inception to January 8, 2025. Two independent reviewers extracted data and assessed the risk of bias. All meta-analyses used random effects models, and the GRADE approach was used to assess the certainty of the evidence. We included 25 RCTs (1,663 participants). Based on usual care, compared to blank treatment, ACE probably reduces body mass index (BMI), waist-to-hip ratio (WHR), and waist circumference (WC), and may enable a greater proportion of patients to achieve a weight loss no less than 5% (relative risk [RR] 1.33, 95% CI 1.15 to 1.55) and may reduce triglycerides (TG). Furthermore, when compared to active comparators, ACE probably enables a greater proportion of patients to achieve a weight loss no less than 5% (RR 1.40, 95% CI 1.11 to 1.76) and reduces WC and may also reduce BMI and TG. All effects were supported by low to moderate certainty evidence. When compared to blank treatment, on the basis of usual care, ACE for obesity associated with PCOS may improve obesity-related outcomes. When compared to active comparators, it may have comparable or greater therapeutic efficacy and fewer adverse events. Such improvements in obesity-related indicators may help alleviate metabolic and reproductive symptoms in women with PCOS. As all included trials were conducted in China, further high-quality studies in diverse populations are needed to confirm the generalizability of these findings.Keywords
This publication has 22 references indexed in Scilit:
- Metabolic and hormonal profiling in polycystic ovarian syndrome: insights into INSR gene variationsMolecular Biology Reports, 2024
- Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trialsThe Lancet, 2024
- Polycystic ovarian syndrome-current pharmacotherapy and clinical implicationsTaiwanese Journal of Obstetrics and Gynecology, 2022
- Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesityClinica Chimica Acta, 2020
- Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and geneticsMetabolism, 2019
- Effectiveness of acupoint catgut embedding therapy for polycystic ovary syndrome: a systematic review and meta-analysisWorld Journal of Acupuncture - Moxibustion, 2017
- Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertilityCochrane Database of Systematic Reviews, 2017
- Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and validJournal of Clinical Epidemiology, 2012
- Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome SocietyFertility and Sterility, 2009
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA StatementJournal of Clinical Epidemiology, 2009